dc.contributor.author | Newton, G | |
dc.contributor.other | Stewart, M | |
dc.coverage.spatial | International | |
dc.date.accessioned | 2020-08-19T09:50:55Z | |
dc.date.issued | 2018-08-30 | |
dc.identifier | GB2018050475W | |
dc.identifier | WO2018154315 | |
dc.identifier.citation | 2018 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3985 | |
dc.description.abstract | The invention provides compounds of formula (I) wherein R is −CH3 or −CH2CH3 and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKKE, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them. (Formula (I)) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Kinase | |
dc.subject | Inflammation | |
dc.subject | Cancer | |
dc.title | 5-(PYRIMIDIN-4-YL)-2-(PYRROLIDIN-1-YL)NICOTINONITRILE COMPOUNDS AS IKKE, TBK1 AND/OR SIK2 KINASES INHIBITORS | |
dc.type | Patent | |
rioxxterms.licenseref.startdate | 2018-08-30 | |
rioxxterms.type | Other | |
pubs.filed-date | 2017-02-23 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.patent-status | PCT | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 3 | |
dc.contributor.icrauthor | Newton, Gary | |